So this just came up on my newsfeed:
"Canada decided to ignore drug/device patents during outbreak under new law
Canada’s emergency legislation on the coronavirus crisis gives the health minister powers to circumvent patent law and ensure medical supplies, medication or vaccines can be produced locally."
https://www.reuters.com/article/us-...idUSKBN21D3HT?feedType=RSS&feedName=worldNews
I read of similar positive stories:
--Costa Rican government urged WHO to create a "voluntary emergency Technology Intellectual Property Pool [TIPP] for broad sharing of the benefits of scientific advancement and its applications in furtherance of the right to health."
-- 'Smiths Group' has made its intellectual property (manufacturing ventilators) available for other manufacturers. AbbVie is allowing generic production of lopinavir/ ritonavir to all countries.
But a few negative ones too:
-- 'Intersurgical' made legal threats re patent infringement, to those who 3D-printed an expensive ventilator valve.
-- US Republicans:
"In February, Rep. Jan Schakowsky, D-Ill., and other House members wrote to Trump pleading that he “ensure that any vaccine or treatment developed with U.S. taxpayer dollars be accessible, available and affordable,” a goal they said couldn’t be met “if pharmaceutical corporations are given authority to set prices and determine distribution, putting profit-making interests ahead of health priorities.”
When the coronavirus funding was being negotiated, Schakowsky tried again.
But many Republicans opposed adding language to the bill that would restrict the industry’s ability to profit, arguing that it would stifle research and innovation.
The final aid package not only omitted language that would have limited drug makers’ intellectual property rights, it also left out language that had been in an earlier draft that would have allowed the federal government to take any action if it has concerns that the treatments or vaccines developed with public funds are priced too high.:
https://theintercept.com/2020/03/13/big-pharma-drug-pricing-coronavirus-profits/
"Canada decided to ignore drug/device patents during outbreak under new law
Canada’s emergency legislation on the coronavirus crisis gives the health minister powers to circumvent patent law and ensure medical supplies, medication or vaccines can be produced locally."
https://www.reuters.com/article/us-...idUSKBN21D3HT?feedType=RSS&feedName=worldNews
I read of similar positive stories:
--Costa Rican government urged WHO to create a "voluntary emergency Technology Intellectual Property Pool [TIPP] for broad sharing of the benefits of scientific advancement and its applications in furtherance of the right to health."
-- 'Smiths Group' has made its intellectual property (manufacturing ventilators) available for other manufacturers. AbbVie is allowing generic production of lopinavir/ ritonavir to all countries.
But a few negative ones too:
-- 'Intersurgical' made legal threats re patent infringement, to those who 3D-printed an expensive ventilator valve.
-- US Republicans:
"In February, Rep. Jan Schakowsky, D-Ill., and other House members wrote to Trump pleading that he “ensure that any vaccine or treatment developed with U.S. taxpayer dollars be accessible, available and affordable,” a goal they said couldn’t be met “if pharmaceutical corporations are given authority to set prices and determine distribution, putting profit-making interests ahead of health priorities.”
When the coronavirus funding was being negotiated, Schakowsky tried again.
But many Republicans opposed adding language to the bill that would restrict the industry’s ability to profit, arguing that it would stifle research and innovation.
The final aid package not only omitted language that would have limited drug makers’ intellectual property rights, it also left out language that had been in an earlier draft that would have allowed the federal government to take any action if it has concerns that the treatments or vaccines developed with public funds are priced too high.:
https://theintercept.com/2020/03/13/big-pharma-drug-pricing-coronavirus-profits/